Szczepanska, Katarzyna and Pockes, Steffen and Podlewska, Sabina and Horing, Carina and Mika, Kamil and Latacz, Gniewomir and Bednarski, Marek and Siwek, Agata and Karcz, Tadeusz and Nagl, Martin and Bresinsky, Merlin and Monnich, Denise and Seibel, Ulla and Kuder, Kamil J. and Kotanska, Magdalena and Stark, Holger and Elz, Sigurd and Kiec-Kononowicz, Katarzyna (2021) Structural modifications in the distal, regulatory region of histamine H-3 receptor antagonists leading to the identification of a potent anti-obesity agent. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 213: 113041. ISSN 0223-5234, 1768-3254
Full text not available from this repository. (Request a copy)Abstract
A series of 4-pyridylpiperazine derivatives with varying regulatory region substituents proved to be potent histamine H-3 receptor (H3R) ligands in the nanomolar concentration range. The most influential modification that affected the affinity toward the H3R appeared by introducing electron-withdrawing moieties into the distal aromatic ring. In order to finally discuss the influence of the characteristic 4-pyridylpiperazine moiety on H3R affinity, two Ciproxifan analogues 2 and 3 with a slight modification in their basic part were obtained. The replacement of piperazine in 3 with piperidine in compound 2, led to slightly reduced affinity towards the H3R (K-i = 3.17 and 7.70 nM, respectively). In fact, 3 showed the highest antagonistic properties among all compounds in this series, hence affirming our previous assumptions, that the 4-pyridylpiperazine moiety is the key element for suitable interaction with the human histamine H-3 receptor. While its structural replacement to piperidine is also tolerated for H3R binding, the heteroaromatic 4-pyridyl moiety seems to be essential for proper ligand-receptor interaction. The putative protein-ligand interactions responsible for their high affinity were demonstrated using molecular modeling techniques. Furthermore, selectivity, intrinsic activity at the H3R, as well as drug-like properties of ligands were evaluated using in vitro methods. Moreover, pharmacological in vivo test results of compound 9 (structural analogue of Abbott's A-331440) clearly indicate that it may affect the amount of calories consumed, thus act as an anorectic compound. (C) 2020 Elsevier Masson SAS. All rights reserved.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | DRUG-LIKENESS; H3 RECEPTOR; BODY-WEIGHT; FOOD-INTAKE; IN-VITRO; DERIVATIVES; TARGET; IDALOPIRDINE; PHARMACOLOGY; INHIBITION; Histamine H-3 receptor; Non-imidazole histamine H3R ligands; Piperazine derivatives, Selective ligands; Molecular docking; Anti-obesity agents |
| Subjects: | 600 Technology > 615 Pharmacy |
| Divisions: | Chemistry and Pharmacy > Institute of Pharmacy > Pharmaceutical/Medicinal Chemistry I (Prof. Elz) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 Sep 2022 12:32 |
| Last Modified: | 13 Sep 2022 12:32 |
| URI: | https://pred.uni-regensburg.de/id/eprint/47317 |
Actions (login required)
 |
View Item |
